Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.
Approval Alert | Zanubrutinib Tablets in Multiple Hematologic Indications
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
3
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
4
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
5